Asahi Kasei has offered 8.9 billion Danish crowns ($1.31 billion) to buy Veloxis, it said on Monday, a deal that would give the Japanese electronic materials maker access to the U.S. pharmaceutical market.
Denmark-based pharmaceutical firm Veloxis has a primary focus on the U.S. market, where it sells the Envarsus XR immunosuppressant used to treat transplant patients.
Asahi Kasei wants to make healthcare a third pillar on top of electronic materials and housing. It aims to double operating profit in its healthcare business to 80 billion yen ($736 million) by the year to March 2026.
The Japanese firm said it had offered 6 crowns per publicly listed share in Veloxis, below Friday’s closing share of 6.6 crowns but a 6% premium to the weighted average share price of the last 30 trading days.
Two major Veloxis shareholders and a group of directors had accepted to tender their shares at 4.5 crowns in cash for each share.
The Veloxis board unanimously decided to recommend the offer to its shareholders and warrant holders.
On Monday, shareholders and warrant holders representing 81.2% of the company’s share capital had agreed to accept the offer, which was conditional on at least 80% accepting.
By Jacob Gronholt-Pedersen
CF Industries Holdings, Inc. (NYSE: CF) today announced that it has closed its acquisition of Incitec Pivot Limited’s (“IPL”) ammonia production complex located in Waggaman, Louisiana. Under the terms of the agreement, CF Industries purchased the Waggaman ammonia plant and related assets for $1.675 billion, subject to adjustments.
The Virgin Atlantic flight was powered entirely by SAF, that was a drop-in replacement for conventional jet fuel, but made solely from sustainable feedstocks. This was enabled through the inclusion of a new bio-based aromatic jet fuel blending component.
Cepsa SA (Madrid) has agreed a deal with C2X, an independent firm owned by AP Moller Holding with AP Moller-Maersk as minority owner, to develop a 300,000 metric tons per year renewable methanol plant at Huelva, Spain.